ANN architecture. حسب Abdelfattah Dani (22226715)

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

Femur length anomalies tend to decrease with later phenology (greater day of year of adulthood anomaly) regardless of elevation or species’ seasonal timing. حسب César R. Nufio (11646271)

Illustration of BSC control using ANN for WECS. حسب Abdelfattah Dani (22226715)

Performance comparison between the OTC-FOC and ANN-BSC. حسب Abdelfattah Dani (22226715)

Training process flowchart of ANN-based MPPT controller. حسب Abdelfattah Dani (22226715)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression حسب Julia Cataldo Lima (22811497)

"…</p> <p>To investigate this, we analyzed the expression of interferon-stimulated genes (ISGs) in 48 SARS-CoV-2-infected patients using real-time polymerase chain reaction (RT-qPCR) and assessed toll-like receptor (TLR7) expression in blood cells via flow cytometry.…"

Introgression decreases allelic shuffling. حسب Enrique J. Schwarzkopf (6579275)

K-means++ clustering algorithm. حسب Zhen Zhao (159931)

"…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …"

Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms. حسب Janaína de Pina Carvalho (12152812)

THD for the stator current i_sb (ANN-BSC). حسب Abdelfattah Dani (22226715)

ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration. حسب Abdelfattah Dani (22226715)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

Mean margin gap. حسب Mizuki Kakizawa (22574740)

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: